Latest Pharma Insights
Executives On The Move: Kai Beckmann Takes The Helm At Merck KGaA
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026
Teva Locks In Tourette’s Frontrunner With $700m Emalex Buy
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026
TytoCare De Novo Could Transform ENT Diagnosis, Accelerating At-Home Care
New York-based TytoCare has secured de novo authorization for its ENT software suite, which works in conjunction with the company’s compatible digital otoscope to provide AI-powered eardrum analysis at home. The de novo classification creates a new regulatory ENT category.
Medtech Insight - April 30, 2026
New York-based TytoCare has secured de novo authorization for its ENT software suite, which works in conjunction with the company’s compatible digital otoscope to provide AI-powered eardrum analysis at home. The de novo classification creates a new regulatory ENT category.
Medtech Insight - April 30, 2026
Xbrane Resubmits Ranibizumab In The US – Can It Succeed This Time?
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026
French HTA Body Slams Pharma Companies For Increasing ‘Unacceptable’ Behavior
The French health technology assessment body, HAS, says a trend had developed recently of pharmaceutical companies trying to undermine its scientific opinions and its independence.
Medtech Insight - April 30, 2026
The French health technology assessment body, HAS, says a trend had developed recently of pharmaceutical companies trying to undermine its scientific opinions and its independence.
Medtech Insight - April 30, 2026
Independent Samsung Bioepis Reports Continued Quarterly Growth
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026
Mum’s The Word On Teva’s Tyvaso Strategy
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026
Astellas Braces For Xtandi LoE By Broadening Strategic Products
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026
Executives On The Move: Kai Beckmann Takes The Helm At Merck KGaA
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026
Recent changes in the industry include C-suite changes at Inventiva and internal moves at Amgen, plus Ardelyx gets a new chief legal officer from Bristol Myers Squibb.
Scrip - April 30, 2026
Teva Locks In Tourette’s Frontrunner With $700m Emalex Buy
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026
Teva bets $700m upfront on a late-stage Tourette's drug that could potentially fill a treatment gap affecting half the patients with the condition.
Scrip - April 30, 2026
Astellas Braces For Xtandi LoE By Broadening Strategic Products
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026
Astellas logs record annual revenue on the back of mainstay growth, while planning to expand Padcev’s indications in multiple markets and moving other key candidates into Phase III.
Scrip - April 30, 2026
TytoCare De Novo Could Transform ENT Diagnosis, Accelerating At-Home Care
New York-based TytoCare has secured de novo authorization for its ENT software suite, which works in conjunction with the company’s compatible digital otoscope to provide AI-powered eardrum analysis at home. The de novo classification creates a new regulatory ENT category.
Medtech Insight - April 30, 2026
New York-based TytoCare has secured de novo authorization for its ENT software suite, which works in conjunction with the company’s compatible digital otoscope to provide AI-powered eardrum analysis at home. The de novo classification creates a new regulatory ENT category.
Medtech Insight - April 30, 2026
French HTA Body Slams Pharma Companies For Increasing ‘Unacceptable’ Behavior
The French health technology assessment body, HAS, says a trend had developed recently of pharmaceutical companies trying to undermine its scientific opinions and its independence.
Medtech Insight - April 30, 2026
The French health technology assessment body, HAS, says a trend had developed recently of pharmaceutical companies trying to undermine its scientific opinions and its independence.
Medtech Insight - April 30, 2026
ACNU’s Digital World Opens Door For Better Trials, Expands Access To Consumer Health Data
Consumers provide health history and related information using digital technologies to access an ACNU OTC, data which can link the purchases to their medication records. Digital capabilities also should bring more efficient and effective studies in play.
HBW Insight - April 29, 2026
Consumers provide health history and related information using digital technologies to access an ACNU OTC, data which can link the purchases to their medication records. Digital capabilities also should bring more efficient and effective studies in play.
HBW Insight - April 29, 2026
Weleda Reinvention Boosts Appeal Among Gen Z
Partnering with influencers helps Weleda to reach younger consumers with established cosmetic brands like Skin Food and new products such as Booster Drops.
HBW Insight - April 29, 2026
Partnering with influencers helps Weleda to reach younger consumers with established cosmetic brands like Skin Food and new products such as Booster Drops.
HBW Insight - April 29, 2026
Puig Says No Decision On Estée Lauder Merger As Talks Continue
Puig and The Estée Lauder Companies are still in discussions on a potential merger, new CEO Jose Manuel Albesa told analysts during an April 28 first quarter presentation.
HBW Insight - April 29, 2026
Puig and The Estée Lauder Companies are still in discussions on a potential merger, new CEO Jose Manuel Albesa told analysts during an April 28 first quarter presentation.
HBW Insight - April 29, 2026
Why Haleon Is Reframing Sustainability Around ‘Enduring Resilience’
Exclusive: Haleon is reframing its sustainability strategy around long-term business resilience, focusing on material risks like climate-threatened ingredient supply chains rather than broad ESG commitments, Haleon’s VP of health inclusivity and sustainability, Sarah McDonald, tells HBW Insight.
HBW Insight - April 29, 2026
Exclusive: Haleon is reframing its sustainability strategy around long-term business resilience, focusing on material risks like climate-threatened ingredient supply chains rather than broad ESG commitments, Haleon’s VP of health inclusivity and sustainability, Sarah McDonald, tells HBW Insight.
HBW Insight - April 29, 2026
AstraZeneca’s Pitch For Crestor 5Mg OTC Switch Includes ‘30M Patient Years’ Safety History
Less than 50% of people who meet guideline criteria for statins are using the drugs. AstraZeneca’s OTC actual use trial shows those consumers are interested in treatment and can accurately self-select 5mg rosuvastatin.
HBW Insight - April 29, 2026
Less than 50% of people who meet guideline criteria for statins are using the drugs. AstraZeneca’s OTC actual use trial shows those consumers are interested in treatment and can accurately self-select 5mg rosuvastatin.
HBW Insight - April 29, 2026
Xbrane Resubmits Ranibizumab In The US – Can It Succeed This Time?
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026
Marking the latest attempt to compete in the US biosimilar Lucentis market, Sweden’s Xbrane Biopharma has once again submitted a BLA for ranibizumab to the US FDA.
Generics Bulletin - April 30, 2026
Independent Samsung Bioepis Reports Continued Quarterly Growth
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026
Strong financials, a growing direct sales footprint, and fresh pipeline deals signal Samsung Bioepis is building for more than just another solid quarter.
Generics Bulletin - April 30, 2026
Mum’s The Word On Teva’s Tyvaso Strategy
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026
Teva has declined to clarify plans around generic Tyvaso despite a 2018 settlement allowing market entry, as strong Phase III data in IPF boosts the drug’s potential and raises questions over a delayed entry into a potentially multi-billion-dollar market.
Generics Bulletin - April 30, 2026
Podcast: Genyro’s Adrian Woolfson On Artificial Biological Intelligence And Genome Writing
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026
Genyro CEO Adrian Woolfson explains how Sidewinder DNA writing and “Artificial Biological Intelligence” could compress vaccine timelines and turn genome?scale design into routine biopharma infrastructure.
In Vivo - April 28, 2026